SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 6/03/11 Nymox Pharmaceutical Corp 20-F/A 12/31/10 7:474K e3 Fil… Computershare/FA |
Document/Exhibit Description Pages Size 1: 20-F/A Annual Report for the Fiscal Year Ended December HTML 23K 31, 2010 - Amendment No. 1 2: EX-4.S Common Stock Private Purchase Agreement Dated HTML 103K November 1, 2010 3: EX-4.T License and Collaboration Agreement Dated December HTML 336K 16, 2010 4: EX-12.A Sox Section 302 CEO Certification HTML 10K 5: EX-12.B Sox Section 302 CFO Certification HTML 10K 6: EX-13.A Sox Section 906 CEO Certification HTML 7K 7: EX-13.B Sox Section 906 CFO Certification HTML 7K
Exhibit 13.a |
Exhibit 13.a
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report on Form 20-F for the year ended December 31, 2010 of Nymox Pharmaceutical Corporation and filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 and the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Nymox Pharmaceutical Corporation.
Date: June 3, 2011
/s/ Paul Averback, MD
Paul Averback, MD
President and Chief Executive Officer
Nymox Pharmaceutical Corporation
This ‘20-F/A’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 6/3/11 | |||
For Period End: | 12/31/10 | 20-F, 6-K | ||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/02/23 Nymox Pharmaceutical Corp. 20-F 12/31/22 105:5.5M Pubco Reporting … Inc/FA 3/30/22 Nymox Pharmaceutical Corp. 20-F 12/31/21 106:6M Pubco Reporting … Inc/FA 3/29/21 Nymox Pharmaceutical Corp. 20-F 12/31/20 103:4.4M Pubco Reporting … Inc/FA |